• Home
  • About
  • UPCOMING WEBINARS & SEMINARS
  • Consultation
  • USP 61/62 FAQ
  • Contact

Barry A. Friedman, PhD LLC

FDA Regulatory Compliance for the Pharmaceutical, Biotechnology and Medical Device Arenas

REGULATORY COMPLIANCE/EXPERT MICROBIOLOGICAL WITNESS CONSULTATION

Regulatory Compliance — Form FDA 483/Warning Letters

With the advent of only 15 calendar days to respond to regulators following a Form FDA 483 (Click Here) or Warning Letter, it is incumbent upon the recipients of these to use the time most productively to minimize any further regulatory actions.

Understanding the Observation becomes the initial step.  Unless the individuals are responding with a thorough understanding, this first receipt of any document by the regulators can be quite devastating since a less than complete or scientifically developed response can create additional regulatory actions.

Understanding what to include within the response goes a long way to assuring the regulatory agency that you understand the Observation(s) and that you are taking immediate actions to comply with their requirements.

Expert Witness Consultation

Whether you are the plaintiff or the defendant within a legal action, there often exists extensive documentation that may require additional examination.  Using my regulatory compliance background — especially in the areas of Quality Compliance, aseptic processing, sterility assurance and microbiology, I can provide explanations and answers to the regulatory commentary that is expected.

Please email me or call 410.493.8406 for an initial consultation

New Reader? Learn More

Connect With Me:

  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Webinar Registration & Information

FREQUENTLY ASKED QUESTIONS:

FDA Form 483 Frequently Asked Questions

USP General Chapter

USP General Chapter 62, Part II

TOP OBSERVATIONS:

FDA’s CDER LISTING OF TOP NINETEEN OBSERVATIONS FOR 2014

FDA CDER Most Frequent Form FDA 483 Observations Fiscal Year 2012

CDER MOST FREQUENTLY CITED DRUG OBSERVATIONS – FISCAL YEAR 2010

Top Posts:

Top Posts for 2012

Top Posts for 2013

Top Posts Year To Date

Recent Posts

  • Upcoming Microbiological Webinars
  • Microbiological Webinars
  • Microbiological Webinars 2020 (Upcoming)
  • General Chapter (USP<60>) on B. cepacia Complex to Issue December 1, 2019
  • Les Produits Chimiques B.G.R., Inc. Receives FDA Warning Letter (07/24/2018) for Failure to Perform Laboratory Testing

Categories

follow us in feedly
  • Home
  • About
  • UPCOMING WEBINARS & SEMINARS
  • Consultation
  • USP 61/62 FAQ
  • Contact
  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter

Thank You For Visiting Barry A. Friedman, PhD LLC - 2015

Welcome To My Blog!
Please enter your name and email below to receive my newsletter.
Your information will *never* be shared or sold to a 3rd party.